Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Capital Expenditures (2020 - 2023)

Candel Therapeutics' Capital Expenditures history spans 4 years, with the latest figure at $438000.0 for Q4 2023.

  • For Q4 2023, Capital Expenditures rose 58.7% year-over-year to $438000.0; the TTM value through Dec 2023 reached $457000.0, down 64.76%, while the annual FY2024 figure was $16000.0, 96.5% down from the prior year.
  • Capital Expenditures for Q4 2023 was $438000.0 at Candel Therapeutics, up from -$288000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.4 million in Q2 2021 and bottomed at -$288000.0 in Q3 2023.
  • The 4-year median for Capital Expenditures is $235000.0 (2021), against an average of $304928.6.
  • The largest annual shift saw Capital Expenditures skyrocketed 372.95% in 2022 before it crashed 137.55% in 2023.
  • A 4-year view of Capital Expenditures shows it stood at $908000.0 in 2020, then plummeted by 44.49% to $504000.0 in 2021, then crashed by 45.24% to $276000.0 in 2022, then surged by 58.7% to $438000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Capital Expenditures are $438000.0 (Q4 2023), -$288000.0 (Q3 2023), and $241000.0 (Q2 2023).